Objectives: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ ritonavir triple therapy. Methods: MODAt is a prospective, multicentre, open-label, non-inferiority, randomized, 96 week trial (NCT01511809) comparing efficacy of atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. Treatment success was defined as no occurrence of confirmed viral rebound (two consecutive HIV-RNA >50 copies/mL) or discontinuation for any cause of the ongoing regimen. Results: The 96 week treatment success was 64% in the atazanavir/ritonavir monotherapy arm and 63% in the triple-therapy arm (difference 1.3%, 95% CI: 217.5 to 20.1). In the atazanavir/ritonavir monotherapy arm, no PI- or NRTI-associated resistance mutations were observed at virological failure and all patients re-suppressed after re-intensification. In the monotherapy arm, treatment failure was more frequent in patients coinfected with hepatitis C virus [64%versus 28%(difference 35.4%, 95%CI: 3.7-67.2)]. Drug-related adverse events leading to discontinuation were 3 (6%) in the atazanavir/ritonavir monotherapy arm and 11 (21.5%) in the triple-therapy arm(P=0.041). The 96 week adjusted mean percentage change in total proximal femur (not at lumbar spine) BMD was +1.16% and 21.64% in the atazanavir/ritonavir monotherapy arm and the triple-therapy arm, respectively (P=0.012). Conclusions: The 96 week analyses suggested that long-term efficacy of atazanavir/ritonavir monotherapy was inferior as compared with atazanavir/ritonavir triple therapy, particularly when administered in subjects coinfected with hepatitis C virus. In the atazanavir/ritonavir monotherapy arm, reintroduction of nucleosides, as needed, was always effective with no new resistance mutation; monotherapy was also associated with a lower incidence of adverse events and improvement in femur BMD.
Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial / L. Galli, V. Spagnuolo, A. Bigoloni, A.D. Monforte, F. Montella, A. Antinori, A. Di Biagio, S. Rusconi, G. Guaraldi, S. Di Giambenedetto, M. Borderi, D. Gibellini, G. Caramatti, A. Lazzarin, A. Castagna, C. Viscoli, A. Di Biagio, A. Parisini, R. Prinapori, F. Mazzotta, S. Lo Caputo, M. Di Pietro, C. Tincati, T. Bini, E. Merlini, M. Puoti, M. Moioli, M. Montella, F. Di Sora, A. Antinori, A. Ammassari, S. Ottou, R. Cauda, S. Di Giambenedetto, M. Galli, S. Rusconi, M. Franzetti, G. Rizzardini, A. Capetti, A. Castagna, V. Spagnuolo, S. Nozza, N. Gianotti, P. Cinque, S. Gerevini, F. Ferretti, A. Lazzarin, L. Galli, E. Carini, A. Bigoloni, C. Vinci, A. Galli, S. Salpietro, A. Poli, C. Mussini, G. Guaraldi. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 71:6(2016 Jun), pp. 1637-1642. [10.1093/jac/dkw031]
Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial
S. Rusconi;C. Tincati;E. Merlini;M. Galli;M. Franzetti;
2016-06
Abstract
Objectives: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ ritonavir triple therapy. Methods: MODAt is a prospective, multicentre, open-label, non-inferiority, randomized, 96 week trial (NCT01511809) comparing efficacy of atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. Treatment success was defined as no occurrence of confirmed viral rebound (two consecutive HIV-RNA >50 copies/mL) or discontinuation for any cause of the ongoing regimen. Results: The 96 week treatment success was 64% in the atazanavir/ritonavir monotherapy arm and 63% in the triple-therapy arm (difference 1.3%, 95% CI: 217.5 to 20.1). In the atazanavir/ritonavir monotherapy arm, no PI- or NRTI-associated resistance mutations were observed at virological failure and all patients re-suppressed after re-intensification. In the monotherapy arm, treatment failure was more frequent in patients coinfected with hepatitis C virus [64%versus 28%(difference 35.4%, 95%CI: 3.7-67.2)]. Drug-related adverse events leading to discontinuation were 3 (6%) in the atazanavir/ritonavir monotherapy arm and 11 (21.5%) in the triple-therapy arm(P=0.041). The 96 week adjusted mean percentage change in total proximal femur (not at lumbar spine) BMD was +1.16% and 21.64% in the atazanavir/ritonavir monotherapy arm and the triple-therapy arm, respectively (P=0.012). Conclusions: The 96 week analyses suggested that long-term efficacy of atazanavir/ritonavir monotherapy was inferior as compared with atazanavir/ritonavir triple therapy, particularly when administered in subjects coinfected with hepatitis C virus. In the atazanavir/ritonavir monotherapy arm, reintroduction of nucleosides, as needed, was always effective with no new resistance mutation; monotherapy was also associated with a lower incidence of adverse events and improvement in femur BMD.
| File | Dimensione | Formato | |
|---|---|---|---|
|
MODAt wk96, JAC 2016.pdf
non disponibili
Tipologia:
Publisher's version/PDF
Dimensione
203.88 kB
Formato
Adobe PDF
|
203.88 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
